ライフサイエンスコーパス: fluorouracil

1 available anti-cancer drugs (imiquimod and 5-fluorouracil).

2 aliplatin and irinotecan plus leucovorin and fluorouracil).

3 nd oxaliplatin followed by bolus and infused fluorouracil).

4 platin, leucovorin, and bolus and infusional fluorouracil).

5 ated apoptosis-inducing ligand (TRAIL) and 5-fluorouracil.

6 easing UBE2C expression in the presence of 5-fluorouracil.

7 agents, namely, cisplatin, docetaxel, and 5-fluorouracil.

8 injury induced by serial administration of 5-fluorouracil.

9 ide analogs, ribavirin, 5-azacytidine, and 5-fluorouracil.

10 cancer cells to the chemotherapeutic agent 5-fluorouracil.

11 nation is due to the in situ generation of 5-fluorouracil.

12 nt cetuximab and two cycles of cisplatin and fluorouracil.

13 ditions of stress hematopoiesis induced by 5-fluorouracil.

14 backbone was capecitabine or leucovorin and fluorouracil.

15 f spheroids to different concentrations of 5-fluorouracil.

16 tive effects of a standard course of topical fluorouracil.

17 ant p53-expressing cell lines resistant to 5-fluorouracil.

18 e colorectal cancer chemotherapeutic agent 5-fluorouracil.

19 gents, including cisplatin, sorafenib, and 5-fluorouracil.

20 sensitizes tumour cells to doxorubicin and 5-Fluorouracil.

21 5-Fluorouracil 1% administered topically 4 times daily for

22 We assessed the effect of fluorouracil 1% eye drops after surgery on recurrence.

23 randomly allocated to receive either topical fluorouracil 1% or placebo four times a day for 4 weeks.

24 atin [80 mg/m(2) intravenously on day 1] and fluorouracil [1 g/m(2) per day intravenously on days 1-4

25 isplatin (60 mg/m(2) on days 1 and 29), with fluorouracil (1000 mg/m(2) per day on days 1-4 and 29-32

26 Direct coupling of N(6)-protected 5-fluorouracil 15 with cyclopentenyl intermediate 13, foll

27 re randomly assigned to receive either mDCF (fluorouracil 2,000 mg/m2 intravenously [IV] over 48 hour

28 All patients received chemoradiation (fluorouracil 225 mg/m(2) per day by continuous infusion

29 y over 5 min, followed by a 46 h infusion of fluorouracil 2400 mg/m(2) repeated every 2 weeks (regime

30 400 mg/m(2) on day 1, and a 46-h infusion of fluorouracil 2400 mg/m(2).

31 LFOX (oxaliplatin, 85 mg/m2 intravenous, and fluorouracil, 2400 mg/m2 intravenous infusion over 46-48

32 as performed on COLO205 cells treated with 5-fluorouracil (3.1, 31, or 310 muM) and oxaliplatin (0.7

33 docetaxel (15-fold), cisplatin (13-fold), 5-fluorouracil (31-fold), camptothecin (7-fold), and gemci

34 400 mg/m(2), irinotecan at 140 mg/m(2), and fluorouracil 400 mg/m(2) bolus followed by 2400 mg/m(2)

35 liplatin 85 mg/m(2) in a 2-h infusion, bolus fluorouracil 400 mg/m(2) on day 1, and a 46-h infusion o

36 0 mg/m(2), leucovorin 400 mg/m(2), and bolus fluorouracil 400 mg/m(2), followed by 2400 mg/m(2) 46-h

37 n, 180 mg/m(2); leucovorin, 400 mg/m(2); and fluorouracil, 400 mg/m(2) bolus followed by 2,400 mg/m(2

38 treatment with the chemotherapeutic agent 5-fluorouracil (5-FU) also induces GzmB production in HSCs

39 uate AUY922, alone and in combination with 5-fluorouracil (5-FU) and cisplatin.

40 5-Fluorouracil (5-FU) and its metabolite 5-fluorodeoxyurid

41 ion stress-inducing chemotherapies such as 5-Fluorouracil (5-FU) and methotrexate (MTX) leading to en

42 gued that colorectal cancer drugs, such as 5-fluorouracil (5-FU) and oxaliplatin, exert such effects,

43 s to unrestricted myelopoietic response to 5-fluorouracil (5-FU) and, in turn, induces exhaustion of

44 topical TSLP inducer, in combination with 5-fluorouracil (5-FU) as an immunotherapy for actinic kera

45 y of the anti-cancer chemotherapeutic drug 5-fluorouracil (5-FU) by prolonging S phase, generating DN

46 The antimetabolite 5-fluorouracil (5-FU) is one of the most widely used chemo

47 ugh colorectal cancer (CRC) treatment with 5-fluorouracil (5-FU) is the first line of therapy for thi

48 ly monitor the effect of the anticancer drug fluorouracil (5-FU) on HCT116 cancer spheroids.

49 ensitive to treatment with the RNA mutagen 5-fluorouracil (5-FU) than wild-type (WT)-ExoN(+), suggest

50 is a target for pemetrexed and the prodrug 5-fluorouracil (5-FU) that inhibit the protein by binding

51 these NPs-treated cancer cells compared to 5-fluorouracil (5-FU) treated cells.

52 Furthermore, cellular stress triggered by 5-fluorouracil (5-FU) treatment potentiates the effects of

53 mode were greatest for the highest DW (i.e., fluorouracil (5-FU)) and K(OW) (i.e., lovastatin (LOVS))

54 pecies using three chemotherapeutic drugs: 5-fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FUDR), an

55 e healthy muVM to a vasotoxic cancer drug, 5-Fluorouracil (5-FU), in comparison with an in vivo mouse

56 unctionalised with Rose Bengal (RB) and/or 5-fluorouracil (5-FU), were assessed as a delivery vehicle

57 ession of miR-520g conferred resistance to 5-fluorouracil (5-FU)- or oxaliplatin-induced apoptosis in

58 Hypoxia reduces sensitivity to 5-fluorouracil (5-FU)-chemotherapy for colorectal cancer (

59 with dark-gold nanoparticles modified with 5-fluorouracil (5-FU)-intercalated nanobeacons that serve

60 o 5-FU for >100 passages, we established a 5-fluorouracil (5-FU)-tolerant line, MKN45/5FU.

61 treatment with the chemotherapeutic agent 5-fluorouracil (5-FU).

62 f the commonly prescribed anti-cancer drug 5-fluorouracil (5-FU).

63 ect on pharmacokinetics of and response to 5-fluorouracil (5-FU).

64 tions conferring resistance to the mutagen 5-fluorouracil (5-FU): nsp12-M611F and nsp12-V553I.

65 To investigate the effect of topical fluorouracil, 5%, cream on photoaging using validated ph

66 articipants were randomized to apply topical fluorouracil, 5%, cream or a vehicle control cream to th

67 photoaging with a standard course of topical fluorouracil, 5%, cream, a finding that may be attributa

68 surgery, women received three cycles of FEC (fluorouracil 500 mg/m(2) plus epirubicin 100 mg/m(2) plu

69 e every 21 days) followed by three cycles of fluorouracil (500 mg/m(2)), epirubicin (100 mg/m(2)), an

70 (75 mg/m(2) on day 1 of cycles 1-4) and FEC (fluorouracil [500 mg/m(2)], epirubicin [75 mg/m(2)], and

71 thymine (T) analogs including uracil (U), 5-fluorouracil (5FU) and 5-hydroxymethyluracil (5hmU) on D

72 like therapy including the drugs CPT11 and 5-fluorouracil (5FU) damaged host immunocompetence in a ma

73 gery, patients received three cycles of FEC (fluorouracil 600 mg/m(2), epirubicin 90 mg/m(2), and cyc

74 received gemcitabine and 499 (51%) received fluorouracil; 675 patients (68%) completed all six cycle

75 on day 1, cisplatin 75 mg/m(2) on day 1, and fluorouracil 750 mg/m(2) on days 1 to 5) followed by the

76 (docetaxel 75 mg/m2, cisplatin 75 mg/m2, and fluorouracil 750 mg/m2 IV over 5 days with granulocyte c

77 reased cell viability when co-incubated with fluorouracil (77.1% vs 46.6%, p=0.037) and irinotecan (4

78 rses of concomitant chemotherapy composed of fluorouracil 800 mg/m(2) and cisplatin 75 mg/m(2).

79 y at clinician's discretion) and intravenous fluorouracil 800 mg/m(2) per day on days 1-4 of radiothe

80 treatment with cyclophosphamide/methotrexate/fluorouracil, AC, and capecitabine, respectively.

81 dose (23%; P = .64) and by similar systemic fluorouracil (active drug) exposure.

82 s were identified between grade 3 or greater fluorouracil AEs and both D949V (odds ratio [OR], 6.3 [9

83 2I with the occurrence of grade 3 or greater fluorouracil AEs and overall hematologic adverse events

84 The incidence of grade 3 or greater fluorouracil AEs in D949V and V732I (DPYD*6) carriers wa

85 nd increased incidence of grade 3 or greater fluorouracil AEs in patients treated with adjuvant fluor

86 To determine the impact of DPYD variants on fluorouracil AEs in patients with stage III CC treated w

87 ants on fluorouracil-related adverse events (fluorouracil AEs).

88 een each DPYD variant and grade 3 or greater fluorouracil AEs.

89 Topical fluorouracil after surgery substantially reduced recurre

90 Mutants sensitive to 5-fluorouracil, an anticancer drug are under-represented w

91 ues 6 and 7 muM for the pyrimidine analogs 5-fluorouracil and 4-thiouracil, respectively.

92 d July, 2014, we assigned 49 participants to fluorouracil and 49 to placebo.

93 owing treatment with the anticancer agents 5-fluorouracil and 5-fluorodeoxyuridine (floxuridine), a 5

94 out two courses of maintenance chemotherapy (fluorouracil and cisplatin at weeks 11 and 14).

95 initial therapy to maintenance chemotherapy (fluorouracil and cisplatin) or no maintenance chemothera

96 er participant was not different between the fluorouracil and control groups at randomization (11.1 v

97 ndard-interval chemotherapy with 3 cycles of fluorouracil and epirubicin-cyclophosphamide every 3 wee

98 l irinotecan monotherapy and those allocated fluorouracil and folinic acid (4.9 months [4.2-5.6] vs 4

99 95% CI 4.8-8.9) vs 4.2 months (3.3-5.3) with fluorouracil and folinic acid (hazard ratio 0.67, 95% CI

100 ssigned either nanoliposomal irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal iri

101 liposomal irinotecan monotherapy (n=151), or fluorouracil and folinic acid (n=149).

102 alent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added la

103 Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a ma

104 oliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this

105 ients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid was 6.1 months (95% CI 4.8

106 ients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutropenia (32 [27%]

107 valent to 100 mg/m(2) of irinotecan base) or fluorouracil and folinic acid.

108 5-Fluorouracil and interferon alpha2b have been found to b

109 ding explanation for the cardiotoxicity of 5-fluorouracil and may be the underlying the mechanism of

110 he largest in anal cancer to date--show that fluorouracil and mitomycin with 50.4 Gy radiotherapy in

111 ld benefit from adjuvant chemotherapy with 5-fluorouracil and oxaliplatin.

112 17) intron repeat, sensitizes the cells to 5-fluorouracil and oxaliplatin.We investigated whether HSP

113 resistant to CRT following treatment with 5-fluorouracil and radiation.

114 emonstrate survival superiority is platinum, fluorouracil, and cetuximab, a monoclonal antibody direc

115 y assigned to CRT alone (CRT arm; docetaxel, fluorouracil, and hydroxyurea plus radiotherapy 0.15 Gy

116 6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superi

117 ich different combinations of oxaliplatin, 5-fluorouracil, and irinotecan were investigated for metas

118 nation with second-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) for metastatic colorectal

119 ation chemotherapy, FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) in a 3D printed fluidic de

120 cetuximab to standard adjuvant oxaliplatin, fluorouracil, and leucovorin chemotherapy (FOLFOX4) in p

121 ve been treated with combination leucovorin, fluorouracil, and oxaliplatin (FOLFOX)-based adjuvant ch

122 evacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the

123 t FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin) chemotherapy with or with

124 atin-based chemotherapy (FOLFOX: leucovorin, fluorouracil, and oxaliplatin) or FOLFOX plus single tre

125 ouracil; capecitabine; FOLFOX-4 (leucovorin, fluorouracil, and oxaliplatin); and modified FOLFOX-6 (m

126 III SCCAC received CRT including cisplatin, fluorouracil, and radiation therapy to the primary tumor

127 son of XELOX or FOLFOX versus leucovorin and fluorouracil, and was also similar for capecitabine-base

128 ere randomly assigned, most of whom received fluorouracil- and oxaliplatin-containing chemotherapy re

129 ed using tamoxifen, paclitaxel, codeine, and fluorouracil as starting points.

130 ith CMF (cyclophosphamide, methotrexate, and fluorouracil) as adjuvant chemotherapy for early breast

131 MT, invasion, migration, and resistance to 5-fluorouracil, as well as metastasis of xenograft tumors

132 opical corticosteroids, vitamin D analogues, fluorouracil, azathioprine, and oral prednisolone with i

133 C) plus local chemotherapy (cisplatin and 5-fluorouracil), (b) chemotherapy alone, (c) RF hypertherm

134 Since the 1990s, fluorouracil-based adjuvant chemotherapy has significant

135 -defined high-risk stage II CRC who received fluorouracil-based adjuvant chemotherapy showed a substa

136 ould gain substantial survival benefits from fluorouracil-based adjuvant chemotherapy.

137 6 patients in 3 independent cohorts received fluorouracil-based adjuvant chemotherapy.

138 disease who could gain survival benefit from fluorouracil-based adjuvant chemotherapy.

139 Overall, adjuvant fluorouracil-based chemotherapy did not improve overall

140 ention of oral mucositis in adults receiving fluorouracil-based chemotherapy for solid cancers, and f

141 The addition of bevacizumab to fluorouracil-based chemotherapy is a standard of care fo

142 them predicted histopathological response to fluorouracil-based chemotherapy regimens, of which the F

143 s without MSI, but have a poor response to 5-fluorouracil-based chemotherapy.

144 uracil AEs in patients treated with adjuvant fluorouracil-based combination chemotherapy.

145 itabine-based regimens versus leucovorin and fluorouracil-based regimens (unadjusted p=0.26).

146 ectal cancer is preoperative, long course (5-fluorouracil-based) CRT.

147 platin 85 mg/m(2) intravenously over 2 h and fluorouracil bolus 400 mg/m(2) intravenously over 5 min,

148 t with a chemotherapy combination containing fluorouracil, capecitabine, and/or irinotecan were rando

149 in patients treated with fluoropyrimidines (fluorouracil, capecitabine, or tegafur-uracil as single

150 xaliplatin and capecitabine); leucovorin and fluorouracil; capecitabine; FOLFOX-4 (leucovorin, fluoro

151 ective of intratumoural transport, including fluorouracil, carmustine, cisplatin, methotrexate, doxor

152 tage, to receive two cycles of cisplatin and fluorouracil (CF; two 3-weekly cycles of cisplatin [80 m

153 hed perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for pati

154 or perioperative epirubicin, cisplatin, and fluorouracil chemotherapy in the Medical Research Counci

155 creased with the addition of oxaliplatin and fluorouracil chemotherapy.

156 Furthermore, they are safer compared to 5-fluorouracil, cisplatin and betulinic acid on NIH/3T3, C

157 a and planned neoadjuvant chemoradiation (5- fluorouracil, cisplatin, 40Gy) followed by 2-field trans

158 classic cyclophosphamide, methotrexate, and fluorouracil (CMF; 600 mg/m(2) cyclophosphamide intraven

159 t to 5-fluoroorotate and hypersensitive to 5-fluorouracil, consistent with loss of UMPS, but remained

160 Participants applied either topical fluorouracil cream, 5% (n = 468), or vehicle control cre

161 Our results indicate that a single course of fluorouracil cream, 5%, effectively reduces AK counts an

162 regimens: continuous intravenous infusional fluorouracil (CVI FU; 225 mg/m(2), 5 days per week), wit

163 Docetaxel, cisplatin, and fluorouracil (DCF) is a standard first-line three-drug c

164 Most patients receiving intravenous 5-fluorouracil develop side effects.

165 with surgery alone, NCRT with cisplatin plus fluorouracil does not improve R0 resection rate or survi

166 5 patients were randomly assigned to receive fluorouracil, doxorubicin, and cyclophosphamide (FAC) x

167 ng CSCs with a genotoxic drug combination (5-fluorouracil, doxorubicin, and cyclophosphamide) generat

168 undred sixty-three patients (57%) received 5-fluorouracil during surgery.

169 irubicin, cisplatin, and continuous-infusion fluorouracil (ECF), irinotecan plus cisplatin (IC), or F

170 lanned cancer treatment was 3 cycles of FEC (fluorouracil, epirubicin [100 mg/m(2) per dose], and cyc

171 itaxel for 12 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after sur

172 itaxel for 12 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after sur

173 itaxel for 12 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide after sur

174 y were randomly assigned to folinic acid and fluorouracil (FF) or oxaliplatin and FF (OFF).

175 FOLFIRINOX (fluorouracil, folinic acid [leucovorin], irinotecan, and

176 urvival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected panc

177 mg infusion over 2 h, and 400 mg/m(2) bolus fluorouracil followed by a 2400 mg/m(2) continuous fluor

178 h, 200 mg leucovorin, and 400 mg/m(2) bolus fluorouracil followed by a 2400 mg/m(2) continuous fluor

179 leucovorin calcium, and then 2400 mg/m2 of 5-fluorouracil for 4 cycles) followed by 5.5 weeks of exte

180 ctide-co-glycolide), polycaprolactone, and 5-fluorouracil for delivering the anti-cancer drug in a pr

181 etinoic acid, dexamethasone, doxorubicin, 5'-fluorouracil, forskolin), sodium dodecyl sulfate (+contr

182 t the in vitro bioorthogonal generation of 5-fluorouracil from a biologically inert precursor by hete

183 cer (mCRC) were randomly assigned to receive fluorouracil (FU) -based chemotherapy either alone or in

184 d postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surg

185 reported a survival benefit with second-line fluorouracil (FU) and oxaliplatin using the oxaliplatin,

186 d a general higher sensitivity to FOLFIRI [5-fluorouracil(FU)+irinotecan+folinic acid] than to FOLFOX

187 The fluorouracil group also had higher complete AK clearance

188 occurred in five (11%) of 47 patients in the fluorouracil group and 17 (36%) of 47 in the placebo gro

189 ugh there were fewer hypertrophic AKs in the fluorouracil group at 6 months (0.23 vs 0.41) (P = .05).

190 After randomization, the fluorouracil group had fewer AKs compared with the contr

191 31 (76%) of 41 assessable patients in the fluorouracil group had grade 3-4 toxicity during adjuvan

192 The fluorouracil group took longer to require the first spot

193 comfort occurred in 43 of 49 patients in the fluorouracil group versus 36 of 49 in the placebo group,

194 taxel group) or fluorouracil plus cisplatin (fluorouracil group) with twice-daily radiation in random

195 dverse effects occurred more commonly in the fluorouracil group, although they were transient and mil

196 OX and FOLFOX groups, and the leucovorin and fluorouracil groups.

197 Gemcitabine, 5-fluorouracil, hydroxyurea, doxorubicin and paclitaxel ha

198 when cell proliferation was suppressed with fluorouracil in apolipoprotein E knock out mice (P<0.05)

199 tions, it was possible to quantify 20 muM of fluorouracil in cell culture medium using a standard FTI

200 apy, yet development of drug resistance to 5-fluorouracil in colorectal cancer cells is the primary c

201 possible to quantify and measure the flux of fluorouracil in situ in living cells treated with an 80

202 ing oxaliplatin, leucovorin, irinotecan, and fluorouracil) in patients with metastatic pancreatic can

203 e in situ quantification of the cancer drug, fluorouracil, in live cells at a therapeutically relevan

204 zes squamous cell carcinoma (SCC) cells to 5-fluorouracil-induced apoptosis and melanoma cells to UVB

205 repopulate upon adoptive transfer or after 5-fluorouracil-induced damage.

206 uracil followed by a 2400 mg/m(2) continuous fluorouracil infusion over 46 h).

207 uracil followed by a 2400 mg/m(2) continuous fluorouracil infusion over 46 h).

208 ia and underwent Nd:YAG LGP, followed by a 5-fluorouracil injection.

209 recovery after sub-lethal irradiation and 5-fluorouracil injection.

210 n 180 mg/m(2) intravenously over 30 min with fluorouracil instead of oxaliplatin (regimen three).

211 travenously on days 1 and 8; and 600 mg/m(2) fluorouracil intravenously on days 1 and 8 of each cycle

212 herapy regimen of folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX),

213 FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin; favorable com

214 s tumour regeneration after treatment with 5-fluorouracil is blocked.

215 ing taxane-containing ICT to cisplatin and 5-fluorouracil is discussed.

216 5-Fluorouracil is effective and well tolerated as a primar

217 liplatin plus capecitabine or leucovorin and fluorouracil is the standard of care for the adjuvant tr

218 of UNG, catalyzes the removal of uracil or 5-fluorouracil lesions that accumulate in DNA following tr

219 wild-type (wt) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus

220 wild-type (wt) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus

221 y demonstrated that addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) signi

222 I) showed superior efficacy as compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI).

223 b in the first-line treatment and subsequent fluorouracil, leucovorin, and irinotecan with or without

224 ermine a preferred strategy between FOLFIRI (fluorouracil, leucovorin, and irinotecan) and ECX (epiru

225 Before random assignment to infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or FO

226 ng yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based

227 We evaluated preoperative infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX)/bevac

228 in patients with stage III CC treated with a fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) regi

229 els to compare the cost and effectiveness of fluorouracil, leucovorin, and oxaliplatin with or withou

230 uated in patients receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) on study N08C

231 ed as modified FOLFOX6 (mFOLFOX6; infusional fluorouracil, leucovorin, and oxaliplatin) versus infusi

232 cer undergoing adjuvant therapy with FOLFOX (fluorouracil, leucovorin, and oxaliplatin) were randomly

233 ect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer ov

234 s recommended in the metastatic setting (eg, fluorouracil, leucovorin, irinotecan, and oxaliplatin an

235 stration that cytotoxic combinations such as fluorouracil, leucovorin, irinotecan, and oxaliplatin as

236 s in arm A received 4 preoperative cycles of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FL

237 Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) tr

238 troduction of bevacizumab, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (F

239 lticenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Col

240 d to preoperative epirubicin, cisplatin, and fluorouracil may be appropriate.

241 and 5-fluorodeoxyuridine (floxuridine), a 5-fluorouracil metabolite.

242 5-fluorouracil, often given with leucovorin, is the most c

243 (the active metabolite of irinotecan) and 5-fluorouracil on cell proliferation under hypoxic conditi

244 Effect of a standard course of fluorouracil on the extent of photodamage as measured us

245 mg/m(2) on days 1 and 29), with intravenous fluorouracil (one dose of 1000 mg/m(2) per day on days 1

246 ectum who had received RCT (45 to 50 Gy with fluorouracil or capecitabine) were included.

247 281 participants randomized to apply topical fluorouracil or placebo were evaluated at baseline, 6 mo

248 ects are observed in feathers treated with 5-fluorouracil or taxol but not with doxorubicin or arabin

249 ith an appropriate cytotoxic chemotherapy (5-fluorouracil) or tyrosine kinase inhibitor (erlotinib),

250 ble treatment option, for which gemcitabine, fluorouracil, or capecitabine can be used as concurrent

251 ubicin (AC) or cyclophosphamide/methotrexate/fluorouracil over single-agent capecitabine in the treat

252 The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizum

253 individual death responses of CRC cells to 5-fluorouracil/oxaliplatin.

254 ere randomly assigned to induction cisplatin/fluorouracil (PF) followed by RT (control arm), concomit

255 PURPOSE Cisplatin plus fluorouracil (PF) induction chemotherapy has been compar

256 of treatment were administered, followed by fluorouracil plus bevacizumab until disease progression.

257 litaxel plus cisplatin (paclitaxel group) or fluorouracil plus cisplatin (fluorouracil group) with tw

258 ternatively, monotherapy with gemcitabine or fluorouracil plus folinic acid can be offered.

259 chemotherapy with FOLFIRINOX (leucovorin and fluorouracil plus irinotecan and oxaliplatin) in patient

260 Fluorouracil plus leucovorin (FU + LV) adjuvant chemothe

261 rs, 10-year OS rates in the bolus/infusional fluorouracil plus leucovorin (LV5FU2) and LV5FU2 plus ox

262 s oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin]).

263 aliplatin (IROX) compared with those given 5-fluorouracil plus oxaliplatin (FOLFOX; cycle 1 mean grad

264 0 to 1, and a favorable comorbidity profile; fluorouracil plus oxaliplatin, irinotecan, or nanoliposo

265 acy of chemoradiotherapy, with CRLX101 and 5-fluorouracil producing the highest therapeutic efficacy.

266 men and three (6%) patients treated with the fluorouracil regimen developed late grade 3-4 radiothera

267 midine dehydrogenase gene (DPYD) variants on fluorouracil-related adverse events (fluorouracil AEs).

268 nd reduced the viability of self-renewing, 5-fluorouracil-resistant Aldefluor positive [Aldefluor(+)]

269 onosphere formation of unsorted and sorted 5-fluorouracil-resistant CSCs.

270 5-Fluorouracil-resistant TYMS T51S, G52S (TYMS(SS)) is res

271 e-rifampicin (RR, 0.14 [95% CI, .05-.36]), 5-fluorouracil (RR, 0.34 [95% CI, .14-.82]), and chlorhexi

272 able comorbidity profile, and gemcitabine or fluorouracil should be offered to patients with either a

273 Repeat challenge with 5-fluorouracil showed that Ghr was dispensable for HSC act

274 reased response to the nucleoside analogue 5-fluorouracil, suggesting that lower levels of this methy

275 fractions during 5.5 weeks, with infusion 5-fluorouracil, surgery in 4 to 6 weeks, and 4 courses of

276 cycles of cyclophosphamide, epirubicin, and fluorouracil (T+CEF), while the other half received 3 cy

277 ne (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) in randomized trials in locoregion

278 mutagenic nucleoside analogs ribavirin and 5-fluorouracil than the WT virus, whereas the lower-fideli

279 their capacities to convert 5-FU to dihydro-fluorouracil, the product of DPD catabolism.

280 zed targeted CONs for targeted delivery of 5-fluorouracil to breast cancer cells.

281 -inhibited by uracil and 4-thiouracil, but 5-fluorouracil toxicity transpires via an alternative mech

282 s of these mice were delayed recovery from 5-fluorouracil treatment and diminished multilineage recon

283 Only upon 5-fluorouracil treatment was HSPC-depleted bone marrow com

284 hermore, using serial transplantations and 5-fluorouracil treatment, we demonstrate that HSCs do not

285 dac8-deficient mice challenged with serial 5-fluorouracil treatment.

286 mice are significantly more susceptible to 5-fluorouracil treatment.

287 graft tumor initiation and was superior to 5-fluorouracil treatment.

288 es PDA cell sensitivity to oxaliplatin and 5-fluorouracil under physiologic low oxygen conditions.

289 between patients who received leucovorin and fluorouracil versus those who received capecitabine in a

290 f VI intermixed with six cycles of cisplatin/fluorouracil/vincristine/doxorubicin (C5VD), and nonresp

291 Topical fluorouracil was demonstrated to be effective in reducin

292 nt amounts of bicarbonate (close to 2 mM), 5-fluorouracil was rapidly removed (within 1 day) through

293 Also, screening of Dam MTase inhibitor 5-fluorouracil was successfully investigated using this fa

294 s, safety, and tolerability of paclitaxel or fluorouracil when added to radiation plus cisplatin foll

295 e were given intraperitoneal injections of 5-fluorouracil, which blocked gastric cell proliferation,

296 SJSA cells treated with 5-fluorouracil, which induces metabolic and genotoxic stre

297 ility after treatment with 1,4-dioxane and 5-fluorouracil, which proves that it can be used for truly

298 th or without oxaliplatin and leucovorin and fluorouracil with or without oxaliplatin groups.

299 or without oxaliplatin versus leucovorin and fluorouracil with or without oxaliplatin has not been di

300 platin and those who received leucovorin and fluorouracil with or without oxaliplatin.